Please assess the completion status of the following clinical trial:

Trial Title: Early Allogeneic Blood Stem Cell Transplantation in High-risk Acute Myeloid Leukemia (AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* newly-diagnosed AML~* either poor risk cytogenetics and/or bad response to the first cycle of IC defined by more than 10% marrow blasts on day 15~* HLA-compatible donor (maximum one HLA-antigen mismatch)~Exclusion Criteria:~* no donor~* Age \< 16 years \> 75 years~* Cardiac insufficiency requiring treatment or symptomatic coronary artery disease~* Hepatic disease, with AST \> 2 times normal~* Severe hypoxemia , pO2 \< 70 mm Hg, with decreased DLCO \< 70% of predicted; or mild hypoxemia, pO2 \< 80 mm Hg with severely decreased DLCO \< 60% of predicted~* Impaired renal function (creatinine \> 2 times normal or creatinine clearance \< 50% for age, weight, height)~* HIV-positive patients due to risk of reactivation or acceleration of HIV replication~* Female patients who are pregnant or breast feeding due to risks to fetus from conditioning regimen and potential risks to nursing infants~* Life expectancy severely limited by diseases other than malignancy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).